Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip’s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended December 5, 2025, including: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer’s rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories Mentioned In This Episode:
- Trump Scores A Drug Pricing Win For Pharma In The UK
- CTAD Notebook: Novo Explains Semaglutide Alzheimer’s Rationale, Roche’s Trontinemab Update
- J&J And Novartis On 2025’s Biggest M&A Deals And What Can Derail A Buyout
- Some CAR-Ts Are Thriving While Others Are Falling Behind. Why?
- Akeso’s Goals Beyond Ivonescimab: ‘We Can Hit Vertex And Regeneron-Level Innovation’
